FGFR3 and endometrial cancer: Regarding FGFR3 mutation in relation to therapeutic response, a previous study illustrated that the FGFR3-targeting drug anlotinib has better treatment efficacy in endometrial cancer than conventional chemotherapy with carboplatin and paclitaxel [51].